WO2001026603A3 - Mesoprogestines (modulateurs de recepteur de progesterone) comme composants de contraceptifs feminins - Google Patents

Mesoprogestines (modulateurs de recepteur de progesterone) comme composants de contraceptifs feminins Download PDF

Info

Publication number
WO2001026603A3
WO2001026603A3 PCT/IB2000/002053 IB0002053W WO0126603A3 WO 2001026603 A3 WO2001026603 A3 WO 2001026603A3 IB 0002053 W IB0002053 W IB 0002053W WO 0126603 A3 WO0126603 A3 WO 0126603A3
Authority
WO
WIPO (PCT)
Prior art keywords
mesoprogestins
female
progesterone receptor
component
contraception
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/002053
Other languages
English (en)
Other versions
WO2001026603A2 (fr
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200020043A priority Critical patent/SI20853A/sl
Priority to IL14841500A priority patent/IL148415A0/xx
Priority to SK298-2002A priority patent/SK2982002A3/sk
Priority to EP00991299A priority patent/EP1605949A2/fr
Priority to BR0013711-1A priority patent/BR0013711A/pt
Priority to HR20020265A priority patent/HRP20020265A2/hr
Priority to AU32150/01A priority patent/AU781835B2/en
Priority to EEP200200103A priority patent/EE200200103A/xx
Priority to JP2001529395A priority patent/JP2003511399A/ja
Priority to UA2002032429A priority patent/UA77150C2/uk
Priority to HU0202515A priority patent/HUP0202515A3/hu
Priority to CA002383650A priority patent/CA2383650A1/fr
Priority to PL00353994A priority patent/PL353994A1/xx
Priority to NZ517470A priority patent/NZ517470A/en
Priority to EA200200284A priority patent/EA006805B1/ru
Priority to MXPA02002186A priority patent/MXPA02002186A/es
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Priority to KR1020027002785A priority patent/KR20020038745A/ko
Publication of WO2001026603A2 publication Critical patent/WO2001026603A2/fr
Publication of WO2001026603A3 publication Critical patent/WO2001026603A3/fr
Priority to BG06441A priority patent/BG106441A/bg
Priority to NO20020998A priority patent/NO20020998L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation de mésoprogestines destinée à la production d'un produit pharmaceutique pour contraception féminine, une préparation pharmaceutique destinée à la contraception féminine ainsi qu'un procédé de contraception féminine par administration de quantités effectives de mésoprogestine dans une contraception féminine recherchée. La mésoprogestine peut, éventuellement, être utilisée en combinaison avec un oestrogène. Les mésoprogestines sont définies comme des composés possédant à la fois des activités agonistes et antagonistes au récepteur de progestérone (PR) in vivo. Elles stabilisent la fonction du PR à un niveau intermédiaire d'activité agoniste et antagoniste. On ne peut pas obtenir des états fonctionnels correspondants avec des progestines ou des antiprogestines. Selon l'invention, les mésoprogestines préférées sont les J867, J912, J956 et J1042.
PCT/IB2000/002053 1999-08-31 2000-08-31 Mesoprogestines (modulateurs de recepteur de progesterone) comme composants de contraceptifs feminins Ceased WO2001026603A2 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
HU0202515A HUP0202515A3 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
SK298-2002A SK2982002A3 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
EP00991299A EP1605949A2 (fr) 1999-08-31 2000-08-31 Mesoprogestines (modulateurs de recepteur de progesterone) comme composants de contraceptifs feminins
BR0013711-1A BR0013711A (pt) 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como um componente de contraceptivos femininos
HR20020265A HRP20020265A2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
IL14841500A IL148415A0 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
EEP200200103A EE200200103A (et) 1999-08-31 2000-08-31 Mesoprogestiinid (progesterooniretseptori modulaatorid) naise kontratseptiivide komponendina
JP2001529395A JP2003511399A (ja) 1999-08-31 2000-08-31 女性避妊薬の成分としてのメソプロゲスチン（プロゲステロン受容体モジュレーター）
UA2002032429A UA77150C2 (en) 1999-08-31 2000-08-31 Use of mesoprogestins j867, j912, or j1042 for female contraception, pharmaceutical composition and kit (variants)
CA002383650A CA2383650A1 (fr) 1999-08-31 2000-08-31 Mesoprogestines (modulateurs de recepteur de progesterone) comme composants de contraceptifs feminins
AU32150/01A AU781835B2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
SI200020043A SI20853A (sl) 1999-08-31 2000-08-31 Mezoprogestini (modulatorji receptorja progesterona) kot sestavina ženskih kontraceptivov
NZ517470A NZ517470A (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
EA200200284A EA006805B1 (ru) 1999-08-31 2000-08-31 Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента женских контрацептивов
MXPA02002186A MXPA02002186A (es) 1999-08-31 2000-08-31 Mesoprogestinas (moduladores del receptor de progesterona) como un componente de los anticonceptivos femeninos.
PL00353994A PL353994A1 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
KR1020027002785A KR20020038745A (ko) 1999-08-31 2000-08-31 여성 피임제 성분으로서의 메조프로게스틴 (프로게스테론수용체 조절물질)
BG06441A BG106441A (bg) 1999-08-31 2002-02-26 Мезопрогестини (модулатори на прогестероновия рецептор) като компоненти на женски контрацептиви
NO20020998A NO20020998L (no) 1999-08-31 2002-02-28 Mesoprogestiner (progesteronreseptormodulater) som en komponent i svangerskapsforebyggelse for kvinner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31
US09/386,133 1999-08-31

Publications (2)

Publication Number Publication Date
WO2001026603A2 WO2001026603A2 (fr) 2001-04-19
WO2001026603A3 true WO2001026603A3 (fr) 2002-01-17

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/002053 Ceased WO2001026603A2 (fr) 1999-08-31 2000-08-31 Mesoprogestines (modulateurs de recepteur de progesterone) comme composants de contraceptifs feminins

Country Status (28)

Country Link
EP (1) EP1605949A2 (fr)
JP (1) JP2003511399A (fr)
KR (1) KR20020038745A (fr)
CN (1) CN1384748A (fr)
AR (1) AR025455A1 (fr)
AU (1) AU781835B2 (fr)
BG (1) BG106441A (fr)
BR (1) BR0013711A (fr)
CA (1) CA2383650A1 (fr)
CO (1) CO5190694A1 (fr)
CZ (1) CZ2002707A3 (fr)
EA (1) EA006805B1 (fr)
EE (1) EE200200103A (fr)
HR (1) HRP20020265A2 (fr)
HU (1) HUP0202515A3 (fr)
IL (1) IL148415A0 (fr)
LT (1) LT5001B (fr)
LV (1) LV12940B (fr)
MX (1) MXPA02002186A (fr)
NO (1) NO20020998L (fr)
NZ (1) NZ517470A (fr)
PE (1) PE20010579A1 (fr)
PL (1) PL353994A1 (fr)
SI (1) SI20853A (fr)
SK (1) SK2982002A3 (fr)
UA (1) UA77150C2 (fr)
WO (1) WO2001026603A2 (fr)
YU (1) YU13902A (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ES2273061T3 (es) * 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
EP1624848A4 (fr) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc Methodes de traitement hormonal faisant appel a des schemas contraceptifs a cycle prolonge
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
WO2006014476A1 (fr) * 2004-07-07 2006-02-09 Wyeth Schémas cycliques de progestérone et trousses d’administration
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
BRPI1014035A2 (pt) * 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309263A2 (fr) * 1987-09-24 1989-03-29 Jencap Research Limited Composition d'hormones et application
DE4332284A1 (de) * 1993-09-20 1995-03-23 Jenapharm Gmbh Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1996012494A1 (fr) * 1994-10-24 1996-05-02 Schering Aktiengesellschaft Antagonistes competitifs de la progesterone permettant de reguler a la demande la fecondite feminine
WO1997041866A1 (fr) * 1996-05-07 1997-11-13 Schering Aktiengesellschaft Augmentation du taux d'implantation apres fecondation in vitro
US5693628A (en) * 1993-09-20 1997-12-02 Jenapharm Gmbh 11-benzaldoxime-estra-diene derivatives, methods for their production and pharmaceuticals containing these compounds
WO1997049407A1 (fr) * 1996-06-25 1997-12-31 Akzo Nobel N.V. Schemas posologiques de progestogene et anti-progestogene
WO1998005679A2 (fr) * 1996-08-05 1998-02-12 Duke University Antagonistes mixtes du recepteur progesterone et techniques de dosage associees
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
WO2000066590A2 (fr) * 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309263A2 (fr) * 1987-09-24 1989-03-29 Jencap Research Limited Composition d'hormones et application
DE4332284A1 (de) * 1993-09-20 1995-03-23 Jenapharm Gmbh Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5693628A (en) * 1993-09-20 1997-12-02 Jenapharm Gmbh 11-benzaldoxime-estra-diene derivatives, methods for their production and pharmaceuticals containing these compounds
WO1996012494A1 (fr) * 1994-10-24 1996-05-02 Schering Aktiengesellschaft Antagonistes competitifs de la progesterone permettant de reguler a la demande la fecondite feminine
WO1997041866A1 (fr) * 1996-05-07 1997-11-13 Schering Aktiengesellschaft Augmentation du taux d'implantation apres fecondation in vitro
WO1997049407A1 (fr) * 1996-06-25 1997-12-31 Akzo Nobel N.V. Schemas posologiques de progestogene et anti-progestogene
WO1998005679A2 (fr) * 1996-08-05 1998-02-12 Duke University Antagonistes mixtes du recepteur progesterone et techniques de dosage associees
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
WO2000066590A2 (fr) * 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CONRAD, CONRAD PROGRAM BIENNIAL REPORT 1998-1999, XP002170202, Retrieved from the Internet <URL:http://www.conrad.org/bi-annual_Report.pdf> [retrieved on 20010620] *
JEWGENOW K ET AL: "Comparative binding affinity study of progestins to the cytosol progestin receptor of endometrium in different mammals.", GENERAL AND COMPARATIVE ENDOCRINOLOGY, vol. 110, no. 2, May 1998 (1998-05-01), pages 118 - 124, XP001006069, ISSN: 0016-6480 *
QUEST M ET AL: "Antigestagens - a new contraceptive method in captive bears?", REPRODUCTION IN DOMESTIC ANIMALS, vol. 34, no. 1, February 1999 (1999-02-01), 32nd Conference on Physiology and Pathology of Reproduction;Hannover, Germany; February 18-19, 1999, pages 32, XP001006070, ISSN: 0936-6768 *

Also Published As

Publication number Publication date
JP2003511399A (ja) 2003-03-25
AU3215001A (en) 2001-04-23
BR0013711A (pt) 2002-05-07
CZ2002707A3 (cs) 2002-11-13
HRP20020265A2 (en) 2004-02-29
SK2982002A3 (en) 2002-07-02
EP1605949A2 (fr) 2005-12-21
AU781835B2 (en) 2005-06-16
AR025455A1 (es) 2002-11-27
SI20853A (sl) 2002-10-31
MXPA02002186A (es) 2002-09-02
CA2383650A1 (fr) 2001-04-19
IL148415A0 (en) 2002-09-12
PL353994A1 (en) 2003-12-15
UA77150C2 (en) 2006-11-15
BG106441A (bg) 2002-09-30
HUP0202515A2 (hu) 2002-12-28
EE200200103A (et) 2003-04-15
CO5190694A1 (es) 2002-08-29
EA006805B1 (ru) 2006-04-28
CN1384748A (zh) 2002-12-11
KR20020038745A (ko) 2002-05-23
LT2002035A (lt) 2002-10-25
NO20020998L (no) 2002-03-14
EA200200284A1 (ru) 2002-10-31
PE20010579A1 (es) 2001-06-04
NO20020998D0 (no) 2002-02-28
HUP0202515A3 (en) 2004-06-28
LT5001B (lt) 2003-03-25
WO2001026603A2 (fr) 2001-04-19
YU13902A (sh) 2006-01-16
LV12940B (en) 2003-06-20
NZ517470A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
WO1995011013A3 (fr) Combinaison d&#39;antagonistes de la progesterone et d&#39;anti-×strogenes a action partiellement agoniste pour l&#39;hormonotherapie substitutive des femmes peri et postmenopausees
AU2002352334A1 (en) Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
WO2002047693A3 (fr) Produits a base d&#39;hormone steroide et leurs procedes de fabrication
WO2000007979A3 (fr) Composes et compositions pour l&#39;administration de principes actifs
CA2188907A1 (fr) Compose pour contraception basee sur les oestrogenes naturels
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2000066590A3 (fr) Composes modulateurs de recepteur de progesterone tetracycliques et procedes
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
HUP0104037A3 (en) Drug delivery device, especially for the delivery of progestins and estrogens
HUP0104718A3 (en) Micronized eplerenone compositions, process for their preparation and use thereof for the preparation of pharmaceutical compositions
WO1998025595A3 (fr) Agents therapeutiques
WO2004110408A3 (fr) Formulation pharmaceutique pour la contraception et le traitement hormonal substitutif
WO2000012623A3 (fr) Utilisation
WO2001026603A3 (fr) Mesoprogestines (modulateurs de recepteur de progesterone) comme composants de contraceptifs feminins
WO2000074649A3 (fr) Compositions ophtalmiques a base d&#39;histamine et leurs utilisations
WO2001015679A3 (fr) Mesoprogestines (modulateurs du recepteur de la progesterone) pour le traitement et la prevention de troubles gynecologiques hormonodependants benins
EP1090639A3 (fr) Composition pharmaceutique contenant un corticoide progestatif et un modulateur sélectif du récepteur oestrogénique
AU9621598A (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
WO2001034126A3 (fr) Mesoprogestines (modulateurs des recepteurs de progesterone) utilises comme composants de compositions de traitement hormonal substitutif
EP0968713A4 (fr) Patchs contenant du nitrate d&#39;isosorbide
AU1556000A (en) Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
WO2001028578A3 (fr) Composition pharmaceutique a base de pglu-glu-pro-nh2 et procede de traitement de maladies et de lesions cerebrales
WO1996028154A3 (fr) Utilisation d&#39;anti-oestrogenes comme contraceptifs masculins
WO2000003678A3 (fr) Acetate de medroxy-progesterone administrable par voie sous-cutanee a des fins contraceptives
IL145373A0 (en) 14b-h-sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-139/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 200020043

Country of ref document: SI

ENP Entry into the national phase

Ref document number: 2000 106441

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 517470

Country of ref document: NZ

Ref document number: PV2002-707

Country of ref document: CZ

Ref document number: 200201614

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 148415

Country of ref document: IL

Ref document number: 2982002

Country of ref document: SK

Ref document number: 2383650

Country of ref document: CA

Ref document number: 32150/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2002 200200231

Country of ref document: RO

Kind code of ref document: A

Ref document number: 2001 529395

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027002785

Country of ref document: KR

Ref document number: 00812308X

Country of ref document: CN

Ref document number: PA/A/2002/002186

Country of ref document: MX

Ref document number: IN/PCT/2002/00247/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200200284

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2002035

Country of ref document: LT

ENP Entry into the national phase

Ref document number: 2002 20020052

Country of ref document: LV

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20020265A

Country of ref document: HR

Ref document number: 200220020052

Country of ref document: LV

WWE Wipo information: entry into national phase

Ref document number: 2000991299

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027002785

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002035

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: PV2002-707

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002035

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: 517470

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517470

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 32150/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000991299

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000991299

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2002-707

Country of ref document: CZ